Login to Your Account

Genentech Buying Out Tanox: $919M Gets Xolair And More

By Randall Osborne

Monday, November 13, 2006
Genentech Inc.'s planned takeover of Tanox Inc. for $20 per share, or $919 million - about $650 million net of cash - would end the royalty payout to Tanox on U.S. sales of the asthma drug Xolair from Genentech, which would also get the royalties Novartis AG has been providing Tanox as part of the companies' three-way deal. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription